Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

NCT04878029 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma

Interventions

DRUG: Cabozantinib S-malate
DRUG: Enfortumab Vedotin
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

Emory University

Collaborators

[object Object]
[object Object]